ATH alterity therapeutics limited

Solanezumab did not work in preclinical AD

  1. 3,119 Posts.
    lightbulb Created with Sketch. 1160

    NEJM today:



    Trial of Solanezumab in Preclinical Alzheimer’s Disease

    List of authors.
    • Reisa A. Sperling, M.D., el al

    Conclusions:
    Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer’s disease. (Funded by the National Institute on Aging and others; A4 ClinicalTrials.gov number, NCT02008357. opens in new tab.)
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
0.000(0.00%)
Mkt cap ! $119.6M
Open High Low Value Volume
1.1¢ 1.1¢ 1.0¢ $46.86K 4.283M

Buyers (Bids)

No. Vol. Price($)
64 25268416 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 18128695 9
View Market Depth
Last trade - 16.10pm 19/09/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.